Dermata Therapeutics, Inc.
Climate Impact & Sustainability Data (2021)
Reporting Period: 2021
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- Initiate two pivotal Phase 3 clinical trials for DMT310 approximately 3-4 months after receiving feedback from the FDA at the EOP2 meeting.
- Initiate a Phase 2 trial for DMT310 in psoriasis in 2022.
- Hold an End of Phase 2 meeting with the FDA in the second half of 2023 and then plan to initiate a Phase 3 program to prepare for an NDA submission.
Short-term Goals:
- Complete development and regulatory approval of DMT310 for acne.
- Complete a Phase 2 trial of DMT310 for the treatment of psoriasis.
- Complete a Phase 2 trial of DMT310 in rosacea.
Environmental Challenges
- Difficulties in obtaining the necessary supply of minipigs required to conduct a required 90-day dermal minipig study.
- Inflation increasing the costs of clinical trials, research and development, and administration.
- Disruptions to the global economy and supply chains resulting in longer lead times and increased costs.
- Difficulties in obtaining the necessary supply of minipigs for a 90-day dermal minipig study.
- Delays and constraints in the global supply chain for minipigs.
- Potential for failures in our internal computer systems, leading to disruptions in manufacturing and development programs.
Mitigation Strategies
- Working closely with suppliers and third parties to minimize the impact of disruptions in lead times and increased costs.
- Exploring alternative manufacturing sources to ensure access to sufficient manufacturing capacity.
- Implementing temporary precautionary measures to minimize the risk of COVID-19 to employees, including remote work and suspension of non-essential travel.
Supply Chain Management
Responsible Procurement
- Exclusive supply agreement with Reka-Farm, LLC for Spongilla raw materials.
Climate-Related Risks & Opportunities
Sustainable Products & Innovation
- DMT310 and DMT410, incorporating Spongilla technology.